(19)
(11) EP 3 337 514 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.04.2022 Bulletin 2022/14

(45) Mention of the grant of the patent:
02.03.2022 Bulletin 2022/09

(21) Application number: 16758029.9

(22) Date of filing: 18.08.2016
(51) International Patent Classification (IPC): 
A61K 47/50(2017.01)
A61K 41/00(2020.01)
A61P 35/00(2006.01)
A61K 47/68(2017.01)
A61K 38/18(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/6803; A61K 47/6849; A61K 41/0071; A61P 35/00; A61K 38/18; A61K 47/6851; Y02A 50/30
(86) International application number:
PCT/US2016/047640
(87) International publication number:
WO 2017/031367 (23.02.2017 Gazette 2017/08)

(54)

COMPOSITION COMPRISING A CONJUGATE COMPRISING A PHTHALOCYANINE DYE LINKED TO A TARGETING MOLECULE FOR PHOTOIMMUNOTHERAPY

ZUSAMMENSETZUNG AUS EINEM KONJUGAT MIT EINEM PHTHALOCYANINFARBSTOFF, DER MIT EINEM ZIELMOLLEKEL FÜR FOTOIMMUNOTHERAPIE VERBUNDEN IST

COMPOSITION COMPRENANT UN CONJUGUÉ COMPRENANT UN COLORANT PHTHALOCYANINE LIÉ À UNE MOLÉCULE CIBLE POUR LA PHOTOIMMUNOTHÉRAPIE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.08.2015 US 201562206776 P
30.10.2015 US 201562249085 P

(43) Date of publication of application:
27.06.2018 Bulletin 2018/26

(60) Divisional application:
20213720.4 / 3827846

(73) Proprietor: Rakuten Medical, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • BIEL, Merrill
    Mendota Heights, MN 51158 (US)
  • MAKINGS, Lewis, R.
    Encinitas, CA 92024 (US)
  • HEIM, Roger
    Del Mar, CA 92014 (US)
  • GARCIA-GUZMAN, Miguel
    San Diego, CA 92130 (US)
  • CHIN, Eileen, Sun
    San Diego, CA 92121 (US)
  • YADAV, Deepak
    San Diego, CA 92129 (US)
  • FONG, Jerry
    San Diego, CA 92130 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)


(56) References cited: : 
WO-A1-2013/009475
US-A1- 2012 010 558
US-B2- 9 358 306
WO-A2-2017/031363
US-A1- 2014 120 119
   
  • SATO KAZUHIDE ET AL: "Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor", MOLECULAR ONCOLOGY, vol. 8, no. 3, 22 January 2014 (2014-01-22), pages 620-632, XP028640450, ISSN: 1574-7891, DOI: 10.1016/J.MOLONC.2014.01.006
  • MITSUNAGA MAKOTO ET AL: "Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.", NATURE MEDICINE DEC 2011, vol. 17, no. 12, December 2011 (2011-12), pages 1685-1691, XP002763622, ISSN: 1546-170X
  • MAKOTO MITSUNAGA ET AL: "Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 8 August 2012 (2012-08-08) , page 345, XP021120474, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-345
  • ALI A. MAAWY ET AL: "Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer", PLOS ONE, vol. 10, no. 3, 23 March 2015 (2015-03-23) , page e0121989, XP55314764, DOI: 10.1371/journal.pone.0121989
  • K. SANO ET AL: "The Effect of Photoimmunotherapy Followed by Liposomal Daunorubicin in a Mixed Tumor Model: A Demonstration of the Super-Enhanced Permeability and Retention Effect after Photoimmunotherapy", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 2, 1 February 2014 (2014-02-01), pages 426-432, XP55337451, US ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-13-0633
  • TAKAHITO NAKAJIMA ET AL: "Improving the Efficacy of Photoimmunotherapy (PIT) using a Cocktail of Antibody Conjugates in a Multiple Antigen Tumor Model", THERANOSTICS, vol. 3, no. 6, 1 January 2013 (2013-01-01) , pages 357-365, XP55219807, AU ISSN: 1838-7640, DOI: 10.7150/thno.5908
  • TADANOBU NAGAYA ET AL: "Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen", PLOS ONE, vol. 10, no. 8, 27 August 2015 (2015-08-27), page e0136829, XP55314754, DOI: 10.1371/journal.pone.0136829
  • Ntc02422979: "Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer", , 17 April 2015 (2015-04-17), XP055624966, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history /NCT02422979?V_1=View#StudyPageTop [retrieved on 2019-09-23]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).